sacubitril and Arrhythmogenic-Right-Ventricular-Dysplasia

sacubitril has been researched along with Arrhythmogenic-Right-Ventricular-Dysplasia* in 1 studies

Other Studies

1 other study(ies) available for sacubitril and Arrhythmogenic-Right-Ventricular-Dysplasia

ArticleYear
Utilization of sacubitril-valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy.
    Future cardiology, 2022, Volume: 18, Issue:7

    Arrhythmogenic right ventricular (RV) cardiomyopathy is an autosomal dominant inherited cardiomyopathy that is characterized by an increased risk of ventricular arrhythmias, sudden cardiac death and, less commonly, heart failure. The authors present the case of a 36-year-old woman with familial lamin cardiomyopathy with positive. The authors present the case of a 36-year-old woman who was found to have arrhythmogenic right ventricular cardiomyopathy, a rare inherited cardiomyopathy. This condition is caused by various mutations that lead to cardiac muscle cells being replaced with fibrofatty tissue and manifests as heart arrhythmias, sudden cardiac death or heart failure. The patient presented with symptoms of right heart failure. Imaging found a new reduction in right ventricular function, confirming the diagnosis of right heart failure. The patient was treated initially with diuretics. However, her symptoms persisted despite treatment and sacubitril–valsartan was started, after which she symptomatically improved. Repeat imaging showed improvement in right ventricular function with sacubitril–valsartan therapy.

    Topics: Adult; Aminobutyrates; Arrhythmogenic Right Ventricular Dysplasia; Biphenyl Compounds; Cardiomyopathies; Contrast Media; Diuretics; Drug Combinations; Female; Gadolinium; Heart Failure; Humans; Valsartan

2022